Show simple item record

dc.contributor.authorOuyang, Z.
dc.contributor.authorLi, H.
dc.contributor.authorZhai, Z.
dc.contributor.authorXu, J.
dc.contributor.authorDass, Crispin
dc.contributor.authorQin, A.
dc.contributor.authorDai, K.
dc.date.accessioned2018-05-18T07:59:57Z
dc.date.available2018-05-18T07:59:57Z
dc.date.created2018-05-18T00:22:54Z
dc.date.issued2018
dc.identifier.citationOuyang, Z. and Li, H. and Zhai, Z. and Xu, J. and Dass, C. and Qin, A. and Dai, K. 2018. Zoledronic acid: Pleiotropic anti-tumor mechanism and therapeutic outlook for osteosarcoma. Current Drug Targets. 19 (5): pp. 409-421.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/67832
dc.identifier.doi10.2174/1573399811666150615145409
dc.description.abstract

© 2018 Bentham Science Publishers. Background: Osteosarcoma is considered the most frequent primary bone malignancy. Lung metastasis is the leading cause of death and the most consistent factor for predicting negative patient outcome in osteosarcoma. Third-generation nitrogen-containing bisphosphonates, such as zoledronic acid, have been shown to reduce osteolysis induced by bone metastasis and exhibit highly selective localization and retention in bone, thus making them attractive agents in the treatment of bone metastasis. Studies have shown that zoledronic acid exerts pleiotropic anti-tumor effects against osteosarcoma cells in vitro, including anti-proliferative, anti-angiogenic, and immuno-modulatory effects. However, the efficacy of zoledronic acid against primary tumor growth and pulmonary metastasis of osteosarcoma is controversial, which has limited its clinical application. Objective: The present review summarizes the controversial effects of zoledronic acid on primary tumor burden and pulmonary metastases in osteosarcoma. We also analyze the clinical effectiveness of zoledronic acid alone and in combination with chemotherapeutic drugs for the treatment of osteosarcoma. Conclusion: Zoledronic acid exhibits diverse anti-tumor effects in osteosarcoma in vitro, however, the in vivo effect is still controversial. Further preclinical and clinical studies are needed to clarify the effects of zoledronic acid in osteosarcoma.

dc.titleZoledronic acid: Pleiotropic anti-tumor mechanism and therapeutic outlook for osteosarcoma
dc.typeJournal Article
dcterms.source.volume19
dcterms.source.number5
dcterms.source.startPage409
dcterms.source.endPage421
dcterms.source.issn1389-4501
dcterms.source.titleCurrent Drug Targets
curtin.departmentSchool of Pharmacy and Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record